75 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
(such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's
8-K
EX-99.1
jx0zb1
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
8voof4j6
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T/A
EX-99
9v1y wbno
25 Sep 23
Third party tender offer statement (amended)
8:48am
SC TO-T
EX-99
po8rv
25 Aug 23
Third party tender offer statement
7:46am
SC TO-C
tcudoetwrx
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
EX-99.1
9j8up0pc qnfdwcy307
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
EX-99.2
0m6l60s5dzi4nrw8c9hb
9 Aug 23
Information about tender offer
4:15pm
8-K
EX-99.1
4i25kwaf
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
vsqo2
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am